Drug Manufacturers May Catch A Break On Medicaid Rebates For Opioid Treatment

Pink Pharma

By: Sarah Karlin-Smith

CMS believes a new law set to take effect this fall will prohibit Medicaid from collecting rebates on opioid use disorder treatments, Congressional offices and Medicaid stakeholders tell the Pink Sheet. Experts worry this interpretation could open the door for CMS to rule other drugs don’t qualify for rebates.

Read more here